Next, whether the effects of TPX2 cause acceleration of a the metabolism and/or clearance of sorafenib, a standard TKI for advanced HCC treatment in HCC cells or HCC tumor tissues were examined by LC–MS/MS. This evidence concerns the gene TPX2 and neoplasm.